Recommended

GSK appoints new CEO
New webinar | Addressing the time-to-result challenge posed by short shelf-life radiopharmaceuticals, register today
Genmab acquires biotech Merus for $8bn
US FDA licensing first for IL-23 inhibitor to treat paediatric psoriasis
Teva makes progress on API business divestment
Takeda to move away from cell therapy
news

Antibody drug has promise as “next frontier” in inflammatory bowel disease

4
SHARES

With its best-in-class potential, the biologic could provide a new treatment option for patients with inflammatory bowel disease (IBD), say Teva Pharmaceuticals and Sanofi.

inflammatory bowel disease (IBD) Sanofi Teva duvakitug antibody

The first randomised, placebo-controlled study to evaluate the impact of an anti-TL1A monoclonal antibody (mAb) in Crohn’s disease has demonstrated for high dose the highest achieved primary endpoint results in ulcerative colitis and Crohn’s with any TL1A mAb. The Phase IIb RELIEVE UCCD study evaluated the human IgG1-λ2 monoclonal antibody duvakitug (TEV’574/SAR447189), which targets TL1A. Participants had moderate-to-severe inflammatory bowel disease (IBD), namely ulcerative colitis and Crohn’s disease.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

Best-in-class potential

In the Phase IIb study, 36.2 percent (low-dose) and 47.8 percent (high-dose) of patients with ulcerative colitis treated with duvakitug achieved clinical remission, Teva Pharmaceuticals and Sanofi shared.

This is in comparison to 20.45 percent who were given placebo. In this cohort at week 14, clinical remission for low dose was reported to be 15.7 percent and 27.4 percent for high dose.

For patients with Crohn’s disease, at week 14, 26.1 percent (low-dose) and 47.8 percent (high-dose) of participants attained endoscopic response compared to 13.0 percent on placebo, 13.0 percent (low dose) and 34.8 percent (high dose), the pharmaceutical companies reported.

“These unprecedented [Phase IIb] results show that duvakitug could represent the next frontier in treating ulcerative colitis and Crohn’s disease”

“These unprecedented results show that duvakitug could represent the next frontier in treating ulcerative colitis and Crohn’s disease. If the magnitude of effect persists in the Phase III programme, we believe we will have a differentiated medicine for IBD patients who are in urgent need of new options,” remarked Dr Houman Ashrafian, PhD, Executive Vice President, Head of R&D at Sanofi.

Detailed findings of this study are set to be presented at a scientific forum in 2025, according to Sanofi and Teva.

Teva and Sanofi’s duvakitug partnership

In a collaborative effort to develop Teva’s duvakitug as a treatment for ulcerative colitis and Crohn’s disease, Sanofi will lead the Phase III clinical development programme. Teva is set to lead commercialisation countries such as Europe and Israel. Additionally, Sanofi will lead commercialisation in North America, Asia and the rest of the world.

Share via
Share via